Trial reportDiabetes, obesity & metabolism2014
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Trial report in Diabetes, obesity & metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Hypertension thErapy With irBesartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.Medicine · 2017Pooled it
- Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV.The Journal of clinical endocrinology and metabolism · 2018Trial
- Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.Metabolic syndrome and related disorders · 2015Trial
- Effect of mineralocorticoid receptor blockade on hippocampal-dependent memory in adults with obesity.Obesity (Silver Spring, Md.) · 2015Trial
- Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles.Cardiovascular drugs and therapy · 2026Review
- Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome.Diabetes, obesity & metabolism · 2026Review
- Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease.American journal of physiology. Cell physiology · 2023Review
- Review
- Review
- Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue.International journal of molecular sciences · 2021Article
- The mineralocorticoid receptor-an emerging player in metabolic syndrome?Journal of human hypertension · 2021Review
- The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.Pharmacology & therapeutics · 2019Review
- Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.Current hypertension reports · 2018Review
- No Significant Role for Smooth Muscle Cell Mineralocorticoid Receptors in Atherosclerosis in the Apolipoprotein-E Knockout Mouse Model.Frontiers in cardiovascular medicine · 2018Article
- Hypertension in Obesity and the Impact of Weight Loss.Current cardiology reports · 2017Review
- The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.American journal of nephrology · 2017Review
- Genomic and rapid effects of aldosterone: what we know and do not know thus far.Heart failure reviews · 2017Review
- The Role of Aldosterone in Obesity-Related Hypertension.American journal of hypertension · 2016Review
- Aldosterone Production and Signaling Dysregulation in Obesity.Current hypertension reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimObese individuals have high aldosterone levels that may contribute to insulin resistance (IR) and endothelial dysfunction leading to obesity-induced cardiovascular disease. We conducted a study to evaluate the effect of mineralocorticoid receptor antagonism on IR and endothelial function in obese individuals. This was a placebo-controlled, double-blind, randomized, parallel-group study (NCT01406015).
methodsThirty-two non-diabetic, obese subjects [body mass index (BMI) 30 to 45 kg/m(2) ] with no other medical problems were randomized to 6 weeks of treatment with spironolactone 50 mg daily or placebo. Insulin sensitivity index (ISI) was assessed by Matsuda method, endothelial function by flow mediated vasodilatation (FMD) of brachial artery and renal plasma perfusion by clearance of para-aminohippurate (PAH).
resultsThere was no change in weight, BMI or plasma potassium during the study period. Treatment with spironolactone led to increases in serum aldosterone (7.6 ± 6.6 vs. 3.2 ± 1.3 ng/dl; p < 0.02, post-treatment vs. baseline) and urine aldosterone (11.0 ± 7 vs. 4.8 ± 2.4 µg/g creatinine; p < 0.01) and decreases in systolic blood pressure (116 ± 11 vs. 123 ± 10 mmHg; p < 0.001). There were no changes in these variables in the placebo group. Neither spironolactone nor placebo treatment had a significant effect on ISI or other indices of glucose metabolism [insulin resistance by homeostatic model assessment (HOMA), area under the curve for insulin, area under the curve for glucose], brachial artery reactivity or the renal plasma perfusion values. Changes in these variables were similar in two groups.
conclusionsWe conclude that 6 weeks of treatment with spironolactone does not change insulin sensitivity or endothelial function in normotensive obese individuals with no other comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.